Atea Pharmaceuticals, Inc. (AVIR)
| Market Cap | 444.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -158.35M |
| Shares Out | 79.67M |
| EPS (ttm) | -1.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 344,832 |
| Open | 5.49 |
| Previous Close | 5.36 |
| Day's Range | 5.46 - 5.61 |
| 52-Week Range | 2.46 - 6.45 |
| Beta | 0.16 |
| Analysts | Buy |
| Price Target | 10.00 (+79.21%) |
| Earnings Date | May 11, 2026 |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AVIR stock is "Buy" and the 12-month stock price target is $10.0.
News
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
As of March 18, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Atea Pharmaceuticals Earnings Call Transcript: Q4 2025
Phase III HCV program advanced with top-line results expected in 2026, supported by strong cash reserves and a focused commercial strategy. HEV pipeline expanded with AT-587 as lead candidate, targeting a significant unmet need. Cash runway extends through 2027.
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Out...
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral ...
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceut...
Atea Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Phase III trials for a new HCV regimen are on track, with top-line data expected this year and NDA filing in early 2027. The regimen offers high efficacy, short duration, and minimal drug interactions, supporting a test-and-treat model. A new Hepatitis E program is advancing toward proof-of-concept studies.
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD ...
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside No...
Atea Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Phase III hepatitis C trials are on track with full enrollment and results expected by mid-2026, while new hepatitis E candidates show strong preclinical promise. The company is preparing for a 2027 launch with robust manufacturing, competitive pricing, and global partnership plans.
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals Transcript: Status Update
A new HCV regimen shows strong efficacy, minimal drug-drug interactions, and high prescriber preference, with phase III trials on track and a focus on simplified, short-duration therapy. Early treatment and streamlined access are emphasized as cost-effective strategies for elimination.
Atea Pharmaceuticals Earnings Call Transcript: Q3 2025
Strong progress in phase 3 HCV trials with top-line results expected in 2026, supported by robust financials and new data highlighting a unique dual mechanism for Bemnifosbuvir. Pipeline expanded to address hepatitis E, targeting significant unmet needs.
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 New Data Show Bemnifosbuvir Has Unique Dual ...
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
BOSTON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A new hepatitis C regimen in phase 3 offers high cure rates, short treatment duration, and minimal drug-drug interactions, addressing a growing and complex patient population. Strong financials support ongoing trials, with broad regulatory support and significant market interest.
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral anti...
Atea Pharmaceuticals Earnings Call Transcript: Q2 2025
Advanced Phase III HCV trials are enrolling on track, supported by strong Phase II efficacy (98% SVR12) and safety data. Financials remain robust with $379.7M in cash and a $25M share buyback, positioning the regimen to disrupt the $3B HCV market if approved.
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Conf...
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada
Atea Pharmaceuticals Transcript: Status Update
A next-generation HCV regimen combining bemnifosbuvir and ruzasvir demonstrated high efficacy, excellent safety, and strong provider and payer support. Phase III trials are underway, aiming to address unmet needs in a growing, younger HCV population with a simplified, short-duration therapy.